THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH [...]
Lipum announces that the company is leading a consortium that has been selected, pending final negotiations, for an EUR 8 million grant from the Horizon Europe Research and Innovation Programme, under the call “Boosting the translation of biotech research into innovative health therapies”. After reviewing the invitation to grant preparation, the consortium has confirmed that [...]
Lipum AB (publ) has published the Q4 interim and year-end report for 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – December 2025Other operating income: 1 929 KSEK (911)Result after financial items: -71 526 KSEK (-55 516)Cash and cash equivalents as of June 30: [...]
Lipum AB (publ) has published the interim report Q3 for the period July-September 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary July – September 2025Other operating income: 457 KSEK (109)Result after financial items: -14 027 KSEK (-1 680)Cash and cash equivalents as of June 30: [...]
The Board of Directors of Lipum AB (publ) (“Lipum”) unanimously recommends the shareholders of Lipum to vote in favour of the completion of the merger between Lipum and Flerie AB (publ) (“Flerie”) announced by press release today 18 November 2025 (the “Merger”). The Board of Directors believes that the Merger will create better conditions for [...]
THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH [...]
Lipum AB (publ) today announced topline results from collaborative studies with Senior Associate Professor Alf Kastbom and team at Linköping University that further support the role of bile salt-stimulated lipase (BSSL) in rheumatoid arthritis (RA). The data from 263 subjects show that patients with recent-onset RA (n=174) have significantly higher BSSL levels in the circulation [...]
Lipum AB (publ) has published the interim report Q2 for the period January-June 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – June 2025Other operating income: 760 KSEK (94)Result after financial items: -36 618 KSEK (-28 109)Cash and cash equivalents as of June 30: [...]
Lipum AB (publ) has appointed Tobias Helgesson as its new Chief Financial Officer (CFO). He succeeds Marina Norberg, who will remain with the company during a transitional period to ensure continuity and a smooth handover. Tobias Helgesson holds a bachelor’s degree in business administration from Lund University. He brings over 20 years of professional experience, [...]
The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025. ContactsOla Sandborgh, CEOola.sandborgh@lipum.se+46 72 218 80 21Web: www.lipum.se About UsLipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. [...]